<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75636</article-id><article-id pub-id-type="doi">10.7554/eLife.75636</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson’s disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-261071"><name><surname>Chen</surname><given-names>Weizhao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6753-4854</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-261072"><name><surname>Zheng</surname><given-names>Qiongping</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1989-9234</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-261073"><name><surname>Huang</surname><given-names>Qiaoying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-261074"><name><surname>Ma</surname><given-names>Shanshan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3004-9468</contrib-id><email>mashsh3@mail.sysu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-261075"><name><surname>Li</surname><given-names>Mingtao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5714-9322</contrib-id><email>limt@mail.sysu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Guangdong Provincial Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Przedborski</surname><given-names>Serge</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01esghr10</institution-id><institution>Columbia University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>10</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e75636</elocation-id><history><date date-type="received" iso-8601-date="2021-11-19"><day>19</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-05-06"><day>06</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-11-15"><day>15</day><month>11</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.11.12.468309"/></event></pub-history><permissions><copyright-statement>© 2022, Chen et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75636-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-75636-figures-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary" xlink:href="10.7554/eLife.80232"/><abstract><p>Lineage reprogramming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson’s disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed in both groups after delivering the adeno-associated virus (AAV) expressing a reporter with shRNA or CRISPR-CasRx to repress astroglial PTBP1, the possibility of AAV leaking into endogenous DAns could not be excluded without using a reliable lineage-tracing method. By adopting stringent lineage-tracing strategy, two other studies show that either knockdown or genetic deletion of quiescent astroglial PTBP1 fails to obtain induced DAns under physiological condition. However, the role of reactive astrocytes might be underestimated because upon brain injury, reactive astrocyte can acquire certain stem cell hallmarks that may facilitate the lineage conversion process. Therefore, whether reactive astrocytes could be genuinely converted to DAns after PTBP1 repression in a PD model needs further validation. In this study, we used <italic>Aldh1l1-CreERT2</italic>-mediated specific astrocyte-lineage-tracing method to investigate whether reactive astrocytes could be converted to DAns in a 6-hydroxydopamine (6-OHDA) mouse model of PD. However, we found that no astrocyte-originated DAn was generated after effective and persistent knockdown of astroglial PTBP1 either in the substantia nigra or in striatum, while AAV ‘leakage’ to nearby neurons was easily observed. Our results confirm that repressing PTBP1 does not convert astrocytes to DAns, regardless of physiological or PD-related pathological conditions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>PTBP1</kwd><kwd>astrocyte-to-neuron conversion</kwd><kwd>lineage reprogramming</kwd><kwd>Parkinson's disease</kwd><kwd>6-OHDA model</kwd><kwd>astrocyte</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Ministry of Science and Technology of China</institution></institution-wrap></funding-source><award-id>the National Key R&amp;D Program of China (2018YFA0108300)</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Mingtao</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>U1801681</award-id><principal-award-recipient><name><surname>Huang</surname><given-names>Qiaoying</given-names></name><name><surname>Ma</surname><given-names>Shanshan</given-names></name><name><surname>Li</surname><given-names>Mingtao</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81771368</award-id><principal-award-recipient><name><surname>Huang</surname><given-names>Qiaoying</given-names></name><name><surname>Ma</surname><given-names>Shanshan</given-names></name><name><surname>Li</surname><given-names>Mingtao</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31871019</award-id><principal-award-recipient><name><surname>Huang</surname><given-names>Qiaoying</given-names></name><name><surname>Ma</surname><given-names>Shanshan</given-names></name><name><surname>Li</surname><given-names>Mingtao</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32070959</award-id><principal-award-recipient><name><surname>Huang</surname><given-names>Qiaoying</given-names></name><name><surname>Ma</surname><given-names>Shanshan</given-names></name><name><surname>Li</surname><given-names>Mingtao</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007162</institution-id><institution>Department of Science and Technology of Guangdong Province</institution></institution-wrap></funding-source><award-id>the Key Realm R&amp;D Program of Guangdong Province (2018B030337001)</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Mingtao</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007162</institution-id><institution>Department of Science and Technology of Guangdong Province</institution></institution-wrap></funding-source><award-id>the Guangdong Provincial Key Laboratory of Brain Function and Disease (2020B1212060024)</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Mingtao</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Repressing astroglial PTBP1 by shRNA or antisense oligonucleotide fails to convert astrocyte to neuron including dopaminergic neuron in a 6-OHDA mouse model of PD.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The emergence and rapid development of in vivo cell reprogramming technology, which converts deleterious astrocytes into functional neurons, holds great promise for neuroregenerative therapy (<xref ref-type="bibr" rid="bib42">Torper and Götz, 2017</xref>). Various groups worldwide have successfully achieved astrocyte-to-neuron (AtoN) conversion by forced expression of different proneural transcription factors (TFs) such as Neurogenin2 (Ngn2) (<xref ref-type="bibr" rid="bib10">Grande et al., 2013</xref>), Mash1 (Ascl1) (<xref ref-type="bibr" rid="bib21">Liu et al., 2015</xref>), NeuroD1 (<xref ref-type="bibr" rid="bib11">Guo et al., 2014</xref>), SOX2 (<xref ref-type="bibr" rid="bib26">Niu et al., 2013</xref>), and various TF combinations (<xref ref-type="bibr" rid="bib32">Rivetti di Val Cervo et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Wu et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Lentini et al., 2021</xref>). In contrast to the TF overexpression approach, by repressing an RNA-binding protein polypyrimidine tract binding protein 1 (PTBP1), two groups have reported that functional neurons including dopaminergic neurons (DAns) could be induced from astrocytes rapidly and efficiently in vivo, reconstructing the nigrostriatal circuit and improving motor deficits in a 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD) (<xref ref-type="bibr" rid="bib30">Qian et al., 2020</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2020</xref>).</p><p>Nevertheless, without substantiating the exact origin of the nascent-induced DAns using a reliable lineage-tracing strategy, these two outstanding works soon arouse widespread debate and argument (<xref ref-type="bibr" rid="bib14">Jiang et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Arenas, 2020</xref>; <xref ref-type="bibr" rid="bib31">Qian et al., 2021</xref>). Most recently, by adopting the stringent lineage-tracing method, two studies arguing against previous findings have been published. One group shows that adeno-associated virus (AAV)-sh<italic>Ptbp1</italic>-induced, presumed astrocyte-converted DAns are not truly converted from astrocytes but are merely AAV-infected endogenous neurons due to virus leakage (<xref ref-type="bibr" rid="bib45">Wang et al., 2021</xref>). Another group reports that no astrocyte-derived neuron, including DAns are generated in multiple brain regions including the substantia nigra and striatum, in astrocyte-specific <italic>Ptbp1</italic> deletion mice (<xref ref-type="bibr" rid="bib3">Blackshaw et al., 2021</xref>). However, both studies only focus on quiescent astrocytes and whether reactive astrocytes could be converted to neurons more effectively after PTBP1 repression requires further verification.</p><p>During brain injury or neurodegeneration, astrocytes become activated and acquire certain characteristics of neural stem cells (NSCs) such as proliferation, Nestin- or Vimentin-immunoreactivity, and multipotency (<xref ref-type="bibr" rid="bib6">Buffo et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Shimada et al., 2012</xref>; <xref ref-type="bibr" rid="bib33">Robel et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Sirko et al., 2013</xref>). Some researchers have claimed that reactive astrocytes with stem cell hallmarks can be reprogrammed to neurons more easily and efficiently than quiescent astrocytes (<xref ref-type="bibr" rid="bib10">Grande et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Guo et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Brulet et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Wan et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Mattugini et al., 2019</xref>). Therefore, we adopted the 6-OHDA PD model with lineage-tracing method to investigate whether reactive astrocytes could truly be converted to neurons including DAns.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Repressing PTBP1 efficiently induces viral-reporter-labeled neurons</title><p>To effectively repress astroglial PTBP1 in vivo, we designed and synthesized AAV (serotype 2/5) expressing EGFP, followed by shRNA targeting mouse <italic>Ptbp1</italic> as previously reported (<xref ref-type="bibr" rid="bib30">Qian et al., 2020</xref>), under the full-length (2.2 kb) <italic>GFAP</italic> promoter (AAV-sh<italic>Ptbp1</italic>). The corresponding virus expressing scramble shRNA (AAV-shscramble) was used as a control (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Viral-reporter-labeled neurons including dopaminergic neurons are induced in the substantia nigra and striatum after adeno-associated virus (AAV)-sh<italic>Ptbp1</italic> delivery.</title><p>(<bold>A</bold>) Schematic of AAV-sh<italic>Ptbp1</italic> and AAV-shscramble vector design and the experimental design. (<bold>B</bold>) Representative images of brain slices co-stained with polypyrimidine tract binding protein 1 (PTBP1) (red) and GFP (green) at indicated timepoints after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the substantia nigra. Scale bar, 50 μm. (<bold>C</bold>) Quantitative data of GFP<sup>+</sup>PTBP1<sup>+</sup> cells ratio from (<bold>B</bold>) are shown. Representative images of brain slices co-stained GFP (green) with tyrosine hydroxylase (TH; purple) or NeuN (red) at indicated timepoints after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the substantia nigra (<bold>D</bold>) and striatum (<bold>F</bold>), the enlarged 3D reconstruction of boxed individual neurons are shown in the lower panel (counterstained with Hoechst–blue). Scale bars: low magnification, 75 μm; high magnification, 10 μm. Quantitative data of GFP<sup>+</sup>NeuN<sup>+</sup> or GFP<sup>+</sup>NeuN<sup>+</sup> cells ratio from the substantia nigra (<bold>D</bold>) and striatum (<bold>F</bold>) are shown in (<bold>E</bold>) and (<bold>G</bold>). n = 3 biological repeats per group. Data are presented as mean ± SEM. * indicates a significant difference between AAV-sh<italic>Ptbp1</italic> and AAV-shscramble (p&lt;0.05). Two-way ANOVA followed by Tukey’s multiple comparisons test is used. (<bold>C</bold>) F(2,12) = 5.297, 1 M: p&lt;0.0001; 2 M: p&lt;0.0001; 3 M: p&lt;0.0001. (<bold>E</bold>) F(2,12) = 5.321, 1 M: p=0.5220; 2 M: p=0.0016; 3 M: p=0.0007. (<bold>G</bold>) F(2,12) = 1.132, 1 M: p=0.0004; 2 M: p=0.0006; 3 M: p=0.0085.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Brain slices co-stained with PTBP1 (red) and GFP (green) at indicated timepoints after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the substantia nigra for <xref ref-type="fig" rid="fig1">Figure 1B, C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Brain slices co-stained GFP (green) with TH (purple) or NeuN (red) at indicated timepoints after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the substantia nigra for <xref ref-type="fig" rid="fig1">Figure 1D, E</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig1-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Brain slices co-stained GFP (green) with TH (purple) or NeuN (red) at indicated timepoints after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the striatum for <xref ref-type="fig" rid="fig1">Figure 1F, G</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig1-data3-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Adeno-associated virus (AAV)-sh<italic>Ptbp1</italic> and AAV-shscramble predominantly infected astrocyte at early timepoint (7dpi).</title><p>(<bold>A</bold>) Representative images of brain slices co-stained with GFP (green) and AldoC (purple), NeuN (red), NG2(purple), or Iba-1(red) 7 days after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the substantia nigra or striatum. Scale bar, 75 μm. (<bold>B</bold>) Ratio of GFP<sup>+</sup> cells in the substantia nigra and striatum that shows positive staining for AldoC, NeuN, NG2, or Iba-1. n = 3 biological repeats per group. Data are presented as mean ± SEM. * indicates a significant difference (p&lt;0.05). Two-way ANOVA (Turkey’s) is used. In the substantia nigra, F(3, 16) = 6.285. AAV-shscramble: AldoC vs NeuN, p&lt;0.0001; AldoC vs NG2, p&lt;0.0001; AldoC vs Iba-1, p&lt;0.0001; AAV-sh<italic>Ptbp1</italic>: AldoC vs NeuN, p&lt;0.0001; AldoC vs NG2, p&lt;0.0001; AldoC vs Iba-1, p&lt;0.0001. In the striatum, F(3, 16) = 0.000. AAV-shscramble: AldoC vs NeuN, p&lt;0.0001; AldoC vs NG2, p&lt;0.0001; AldoC vs Iba-1, p&lt;0.0001; AAV-sh<italic>Ptbp1</italic>: AldoC vs NeuN, p<italic>&lt;</italic>0.0001; AldoC vs NG2, p&lt;0.0001; AldoC vs Iba-1, p&lt;0.0001.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Brain slices co-stained with GFP (green) and AldoC (purple), NeuN (red), NG2 (purple), or Iba-1 (red) 7days after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the substantia nigra or striatum for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig1-figsupp1-v2.tif"/></fig></fig-group><p>First, to verify the cell specificity of AAV-sh<italic>Ptbp1</italic> and AAV-shscramble, we performed immunostaining and GFP<sup>+</sup> cell counting 7 days after AAV delivery into the substantia nigra and striatum, respectively. Our results showed that both AAVs mostly infected astrocytes (AldoC<sup>+</sup>), but not neurons (neuronal nuclei, NeuN<sup>+</sup>), NG2-glia (NG2<sup>+</sup>), or microglia (Iba-1<sup>+</sup>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><p>Next, to investigate whether repressing astroglial PTBP1 could gradually convert astrocytes to DAns in the substantia nigra and striatum, brain slices of different timepoints (1, 2, and 3 months) after AAV injection were collected for immunostaining analysis. PTBP1 expression was not affected by AAV-shscramble, but was downregulated to undetectable levels by AAV-sh<italic>Ptbp1</italic> in GFP<sup>+</sup> cells from 1 to 3 months (<xref ref-type="fig" rid="fig1">Figure 1B, C</xref>), indicating astroglial PTBP1 was consistently repressed.</p><p>The pan-neuronal marker NeuN and the DAn marker tyrosine hydroxylase (TH) were then co-stained with GFP. The results showed that very few GFP<sup>+</sup>NeuN<sup>+</sup> cells (approximately 2.39%) were detected even at 3 months after AAV-shscramble injection, while remarkable GFP<sup>+</sup>NeuN<sup>+</sup> cells were detected, with 12.65 ± 1.56%, 41.10 ± 1.98%, and 46.09 ± 12.9% GFP<sup>+</sup> cells expressing NeuN, and with 8.99 ± 1.99%, 30.40 ± 3.03%, and 37.93 ± 9.92% expressed TH, at 1, 2, and 3 months after AAV-sh<italic>Ptbp1</italic> injection in the substantial nigra (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>). In the striatum, only GFP<sup>+</sup>NeuN<sup>+</sup> cells, but not GFP<sup>+</sup>TH<sup>+</sup> cells, were detected after AAV-sh<italic>Ptbp1</italic> delivery (<xref ref-type="fig" rid="fig1">Figure 1E, F</xref>). These results highly resemble results of Qian’s study (<xref ref-type="bibr" rid="bib30">Qian et al., 2020</xref>) but against that of Zhou’s study (<xref ref-type="bibr" rid="bib52">Zhou et al., 2020</xref>).</p><p>However, these results are not sufficient to prove that astrocytes were truly converted to neurons including DAn, as AAV-mediated gene expression could be ‘leaked’ into neurons as indicated by a recent study (<xref ref-type="bibr" rid="bib45">Wang et al., 2021</xref>). Thus, more solid evidence such as lineage-tracing is needed to verify the exact origin of these viral-reporter-labeled neurons and DAns.</p></sec><sec id="s2-2"><title>PTBP1 repression fails to convert quiescent astrocytes to DAns</title><p>Genetic lineage-tracing (<xref ref-type="bibr" rid="bib17">Kretzschmar and Watt, 2012</xref>) has been widely recognized as the most convincing strategy for cell source identification and is generally performed by combining cell-specific Cre recombinase-expressing mice with Cre-activated reporter mice. <italic>Aldh1l1-CreERT2</italic> mice with the highest specificity to target astrocytes (<xref ref-type="bibr" rid="bib38">Srinivasan et al., 2016</xref>) were chosen to cross-breed with a reporter mouse <italic>Rpl22<sup>lsl-HA</sup></italic> (Ribotag) (<xref ref-type="bibr" rid="bib35">Sanz et al., 2009</xref>), in which the endogenous ribosomal protein Rpl22 was tagged with three copies of the hemagglutinin (HA) epitope after Cre-mediated recombination (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). After Tamoxifen (TAM)-mediated induction of CreERT2 activity, almost all of the AldoC-positive astrocytes were specifically labeled with the HA epitope (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) and barely no HA leaky expression was observed in the neurons of the substantia nigra and striatum of <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>No viral-reporter-labeled neuron including dopaminergic neuron is derived from quiescent astrocytes AAV-sh<italic>Ptbp1</italic> delivery.</title><p>(<bold>A</bold>) Schematic of breeding strategy of <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> lineage-tracing mice. (<bold>B</bold>) Experimental design of Tamoxifen (TAM) induction and representative images of the substantia nigra or striatum of <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice co-stained hemagglutinin (HA) (red) with pan-astrocyte marker AldoC (green) and tyrosine hydroxylase (TH) (purple) 2 weeks after TAM administration. Scale bar, 100 μm. (<bold>C</bold>) Schematic of experimental design. Representative images of brain slices co-stained GFP (green), HA (red) with TH (purple) in the substantia nigra (<bold>D</bold>) or with NeuN (purple) in striatum (<bold>E</bold>) 3 months after AAV-sh<italic>Ptbp1</italic> delivery. n = 3 biological repeats per group. Arrows indicate GFP/TH (<bold>D</bold>) or GFP/NeuN (<bold>E</bold>) double positive neurons that are HA negative. Scale bar, 75 μm.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Indicated brain regions of <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice co-stained hemagglutinin (red) with pan-astrocyte marker AldoC (green) and tyrosine hydroxylase (purple) 2 weeks after Tamoxifen administration for <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Brain slices co-stained GFP (green), HA (red) with TH (purple) in the substantia nigra 3 months after AAV-sh<italic>Ptbp1</italic> delivery for <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig2-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Brain slices co-stained GFP (green), hemagglutinin (red) with NeuN (purple) in the striatum 3 months after adeno-associated virus-sh<italic>Ptbp1</italic> delivery for <xref ref-type="fig" rid="fig2">Figure 2E</xref><bold>.</bold></title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig2-data3-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Representative images of brain slices co-stained GFP (green), hemagglutinin (HA; red) with tyrosine hydroxylase (TH; purple) in the substantia nigra (<bold>A</bold>) or with NeuN (purple) in striatum (<bold>B</bold>) 3 months after adeno-associated virus (AAV)-shscramble delivery.</title><p>n = 2 biological repeats per group. Scale bar, 75 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Two weeks after TAM induction, <italic>Aldh1l1-CreERT2:Rpl22<sup>lsl-HA</sup></italic> mice were injected with AAV-sh<italic>Ptbp1</italic> and AAV-shscramble into the substantia nigra or striatum to verify whether GFP<sup>+</sup>TH<sup>+</sup> or GFP<sup>+</sup>NeuN<sup>+</sup> cells were originated from HA-labeled astrocytes (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Three months later, the mice were sacrificed for triple immunostaining for GFP, HA and NeuN, or for GFP, HA, and TH. Through exhaustive examination of the whole midbrain and striatum, no GFP<sup>+</sup>TH<sup>+</sup> or GFP<sup>+</sup>NeuN<sup>+</sup> cells that were simultaneously HA-positive could be detected in either AAV-sh<italic>Ptbp1</italic> (<xref ref-type="fig" rid="fig2">Figure 2D, E</xref>) or AAV-shscramble (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–B</xref>) treated mice.</p><p>Therefore, the lineage-tracing results clearly illustrat that PTBP1 repression fails to convert quiescent astrocytes to neurons including DAns, which is consistent with recent studies (<xref ref-type="bibr" rid="bib45">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">Blackshaw et al., 2021</xref>).</p></sec><sec id="s2-3"><title>PTBP1 repression also fails to convert reactive astrocytes to DAns in a 6-OHDA model</title><p>Many studies have suggested that reactive astrocytes may acquire certain characteristics of NSC upon brain injury, which may promote the AtoN conversion process (<xref ref-type="bibr" rid="bib10">Grande et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Guo et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Brulet et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Wan et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Mattugini et al., 2019</xref>). To verify whether repression of PTBP1 could convert reactive astrocytes to neurons including DAns, we injected AAV-shscramble or AAV-sh<italic>Ptbp1</italic> in the substantia nigra or striatum of the <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice 3 weeks after the 6-OHDA lesion (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>No neuron including dopaminergic neuron (DAn) is derived from reactive astrocytes in 6-hydroxydopamine (6-OHDA) model after polypyrimidine tract binding protein 1 (PTBP1) repression.</title><p>(<bold>A</bold>) Schematic of experimental design. (<bold>B</bold>) Representative images of the substantia nigra or striatum after 6-OHDA lesion co-stained with tyrosine hydroxylase (TH; green) and GFAP (red). Scale bar, 200 μm for the substantia nigra and 50 μm for the striatum. (<bold>C</bold>) Representative images of brain slices of <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice subjected to 6-OHDA lesion and adeno-associated virus (AAV)-sh<italic>Ptbp1</italic> or AAV-shscramble injection in substantia (upper panel) and striatum (lower panel), co-stained with GFP (cyan), hemagglutinin (HA; red) and NeuN (green) or TH(green). Scale bar, 50 μm. Number of NeuN<sup>+</sup> neurons (<bold>D</bold>) and TH<sup>+</sup> DAns (<bold>E</bold>) in the substantia nigra 3 months after treatment with AAV-sh<italic>Ptbp1</italic> or AAV-shscramble on 6-OHDA lesioned mice. n = 5 mice for AAV-shscramble group; n = 8 mice for AAV-sh<italic>Ptbp1</italic> group. (<bold>F</bold>) Apomorphine-induced rotation test before and 3 months after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery on 6-OHDA lesioned mice. n = 8 mice for AAV-sh<italic>Ptbp1</italic> group; n = 5 mice for AAV-shscramble group. Data are presented as mean ± SEM. Unpaired t test is used in (<bold>D</bold>) F(4, 7) = 3.266, p=0.4627 and (<bold>E</bold>) F(4, 7) = 3.856 p=0.5534. Unpaired t test is used in (<bold>F</bold>) 0 M AAV-sh<italic>Ptbp1</italic> vs AAV-shscramble F(7, 4) = 3.59, p=0.3669; 3 M AAV-sh<italic>Ptbp1</italic> vs AAV-shscramble F(7, 4) = 2.157, p=0.7915. Paired t test is used in (<bold>F</bold>), AAV-shscramble 3 M vs 0 M: p=0.0489, df = 4; AAV-sh<italic>Ptbp1</italic> 3 M vs 0 M: p=0.068, df = 7.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Brain slices of the substantia nigra or striatum after 6-OHDA lesion, co-stained with TH (green) and GFAP (red) for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig3-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Brain slices of <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice subjected to 6-OHDA lesion and AAV-shPtbp1 or AAV-shscramble injection in substantia or striatum, co-stained with GFP (green) and HA (red), or NeuN (green) and HA (red), or TH(green) and HA (red) for <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig3-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Original data and statistical analysis of <xref ref-type="fig" rid="fig3">Figure 3D and E</xref> for <xref ref-type="fig" rid="fig3">Figure 3D&amp;E</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig3-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Original data and statistical analysis of <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig3-data4-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig3-v2.tif"/></fig><p>Our results showed that 6-OHDA induced severe lesions in the nigrostriatal pathway, characterized by significantly reduced numbers of DAns in the substantia nigra and remarkably decreased densities of TH<sup>+</sup> fibers in the striatum (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Meanwhile, astrocytes became remarkably activated, as indicated by classic cytoskeletal and morphological changes, including hypertrophy of the main processes and cell bodies and upregulation of intermediate filament protein GFAP (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). However, under such circumstance, no NeuN<sup>+</sup> neurons including TH<sup>+</sup> DAns positive for HA, could be detected, and no obvious morphological changes of astrocytes (indicated by HA staining) were observed after PTBP1 repression (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), suggesting that neither AtoN nor astrocyte-to-DAn (AtoDAn) conversion occurred. Moreover, the number of NeuN<sup>+</sup> neurons (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) and TH<sup>+</sup> DAns (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) did not increase after AAV-sh<italic>Ptbp1</italic> delivery into the substantia nigra compared with AAV-shscramble delivery. The motor deficits induced by 6-OHDA lesion (reflected by apomorphine-induced rotation) were not improved by AAV-sh<italic>Ptbp1</italic> injection, either (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><p>Together, these data demonstrate that repressing PTBP1 also fails to generate DAns from reactive astrocytes in a mouse 6-OHDA model of PD.</p></sec><sec id="s2-4"><title>ASO-mediated PTBP1 repression still fails to convert reactive astrocytes to DAns in a 6-OHDA mouse model of PD</title><p>To rule out the possibility that AAV toxicity (<xref ref-type="bibr" rid="bib15">Johnston et al., 2021</xref>) restrained the AtoN conversion process, we synthesized antisense oligonucleotide (ASO) against mouse <italic>Ptbp1</italic> as an alternative strategy for PTBP1 repression (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Immunofluorescence results showed that ASO was distributed broadly in the midbrain, as indicated by ASO-attached Cy3, and astroglial PTBP1 was significantly downregulated for 2 months after ASO-<italic>Ptbp1</italic> delivery compared to ASO-Ctrl delivery (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>). Western blot analysis of the midbrain further confirmed the knockdown efficiency of ASO-<italic>Ptbp1</italic> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C, D</xref>). Using brain slices from the same mice, we did not find any astrocyte-originated neurons (YFP<sup>+</sup>NeuN<sup>+</sup>) or DAns (YFP<sup>+</sup>TH<sup>+</sup>) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), suggesting that no neurons, including DAns, were converted from quiescent astrocytes after ASO-<italic>Ptbp1</italic> delivery. Next, we injected ASO-<italic>Ptbp1</italic> or ASO-Ctrl into the substantia nigra of 6-OHDA lesioned <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Two months after ASO delivery, we still could not find any neurons including DAns positive for HA (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), indicating that no neurons, including DAn, were generated from reactive astrocytes. Furthermore, the motor deficits of the 6-OHDA lesioned mice were not alleviated by 2 months of ASO-<italic>Ptbp1</italic> treatment (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), similar to those of ASO-Ctrl (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>No neuron including dopaminergic neuron is derived from astrocytes with or without 6-hydroxydopamine (6-OHDA) lesion after antisense oligonucleotide (ASO)-mediated polypyrimidine tract binding protein 1 (PTBP1) repression.</title><p>(<bold>A</bold>) Schematic of experimental design. (<bold>B</bold>) Representative images of the brain slices of <italic>Aldh1l1-CreERT2;Rosa26<sup>lsl-YFP</sup></italic> mice co-stained with YFP (green) and NeuN (red) or tyrosine hydroxylase (TH; purple) after ASO-<italic>Ptbp1</italic> or ASO-Ctrl delivery in the substantia nigra. Scale bar, 75 μm. n = 6 mice for ASO-Ctrl group; n = 5 mice for ASO-<italic>Ptbp1</italic> group. (<bold>C</bold>) Schematic of experimental design. (<bold>D</bold>) Representative images of brain slices of 6-OHDA lesioned <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice after ASO-<italic>Ptbp1</italic> delivery in substantia nigra, co-stained with hemagglutinin (HA; green) and NeuN (red) or TH (purple). Scale bar, 75 μm. n = 2 mice for ASO-Ctrl group; n = 3 mice for ASO-<italic>Ptbp1</italic> group. (<bold>E</bold>) Apomorphine-induced rotation test before and 2 months after ASO-<italic>Ptbp1</italic> delivery in substantia nigra on 6-OHDA lesioned mice (n = 3 biological repeats). Data are presented as mean ± SEM. Paired t test is used in (<bold>E</bold>), p=0.1435, df = 2.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Brain slices of <italic>Aldh1l1-CreERT2;Rosa26<sup>lsl-YFP</sup></italic> mice co-stained with YFP (green) and NeuN (red) or TH (purple) after ASO-<italic>Ptbp1</italic> or ASO-Ctrl delivery in the substantia nigra for <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig4-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Brain slices of 6-OHDA lesioned <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> mice after ASO-<italic>Ptbp1</italic> delivery in substantia nigra, co-stained with HA (green) and NeuN (red) or TH (purple) for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig4-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original data and statistical analysis of <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig4-data3-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Knockdown efficiency of PTBP1 by ASO.</title><p>(<bold>A</bold>) In vivo knockdown efficiency of antisense oligonucleotide (ASO) by immunofluorescence. Representative images of the brain slices of <italic>Aldh1l1-CreERT2;Rosa26<sup>lsl-YFP</sup></italic> mice co-stained with polypyrimidine tract binding protein 1 (PTBP1; purple), YFP (green), and Cy3 (red) after ASO-<italic>Ptbp1</italic> or ASO-Ctrl delivery in the substantia nigra. n = 3 mice for ASO-Ctrl group; n = 5 mice for ASO-<italic>Ptbp1</italic> group. Scale bar, 75 μm. (<bold>B</bold>) Quantitative data of relative PTBP1 intensity from (<bold>A</bold>) are shown. Unpaired t test is used. p&lt;0.0001, F(2, 4) = 2.868. (<bold>C</bold>) In vivo knockdown efficiency of ASO by western blot, normalized against β-actin in mouse midbrain delivered with ASO-<italic>Ptbp1</italic> or ASO-Ctrl (n = 3 biological repeats, respectively). (<bold>D</bold>) Quantitative data of relative PTBP1/β-actin ratio from (<bold>C</bold>) are shown. Unpaired t test is used. p=0.016, F(2, 2) = 6.268.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Brain slices of <italic>Aldh1l1-CreERT2;Rosa26<sup>lsl-YFP</sup></italic> mice co-stained with PTBP1 (purple), YFP (green), and Cy3 (red) after ASO-<italic>Ptbp1</italic> or ASO-Ctrl delivery in the substantia nigra for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Apomorphine-induced rotation test before and 2 months after antisense oligonucleotide (ASO)-Ctrl delivery in substantia nigra on 6-hydroxydopamine lesioned mice (n = 1 biological repeat).</title><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Original data and statistical analysis of <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-75636-fig4-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75636-fig4-figsupp2-v2.tif"/></fig></fig-group><p>These data demonstrate that repressing astroglial PTBP1 via ASO also fails to generate DAns from either quiescent or reactive astrocytes in a 6-OHDA mouse model of PD.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, through stringent and convincing lineage-tracing technology, we substantiated that neither AAV-shRNA- nor ASO-mediated astroglial PTBP1 repression could achieve AtoN or AtoDAn conversion either in the substantia nigra or in the striatum of a 6-OHDA mouse model of PD.</p><p>We first used AAV expressing EGFP followed by sh<italic>Ptbp1</italic> under the full-length <italic>GFAP</italic> promoter to repress astroglial PTBP1 and AAV-shscramble as a control. Both AAV constructs were predominantly expressed in astrocytes 7 days post-infection. After 1–3 months of infection, AAV-sh<italic>Ptbp1</italic> allowed for low levels of reporter protein (GFP) expression in neurons, whereas AAV-shscramble-mediated GFP expression was still restricted to astrocytes. Without stringent lineage-tracing, the result can be easily misinterpreted as PTBP1 repression-mediated AtoN conversion. The reason why AAV-sh<italic>Ptbp1</italic> rather than AAV-shscramble leaked into neurons is currently unclear. According to a recent study, coding sequences of some proneural genes, such as <italic>Neurod1,</italic> could activate <italic>GFAP</italic> promoter elements in cis and drive the expression of the viral reporter gene in neurons (<xref ref-type="bibr" rid="bib45">Wang et al., 2021</xref>). We presume that the sh<italic>Ptbp1</italic> sequence might function similarly to <italic>Neurod1</italic>, activating <italic>GFAP</italic> promoter and driving GFP expression in neurons at a relatively low level.</p><p>It has been reported that AAV can exert toxic effects on doublecortin (DCX)<sup>+</sup> neuroblasts or neural progenitor cells (<xref ref-type="bibr" rid="bib15">Johnston et al., 2021</xref>), which might render the virus-infected astrocytes unable to convert into neurons. After reviewing previous studies of in vivo glia-to-neuron conversion, we found that DCX<sup>+</sup> intermediate cells could hardly be detected using AAV for gene manipulation (<xref ref-type="bibr" rid="bib21">Liu et al., 2015</xref>; <xref ref-type="bibr" rid="bib11">Guo et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Brulet et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Mattugini et al., 2019</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Lai et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Leib et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Xiang et al., 2021</xref>; <xref ref-type="bibr" rid="bib51">Zheng et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Torper et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Pereira et al., 2017</xref>). In contrast, DCX<sup>+</sup> intermediate cells can usually be seen in most lentivirus (LV)/retrovirus (RV)-mediated glia-to-neuron conversion studies in vivo <italic>(</italic><xref ref-type="bibr" rid="bib10">Grande et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Guo et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Niu et al., 2013</xref>; <xref ref-type="bibr" rid="bib5">Buffo et al., 2005</xref>; <xref ref-type="bibr" rid="bib9">Gascón et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Torper et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Rivetti di Val Cervo et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Magnusson et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Niu et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Su et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Zhang et al., 2022</xref>; <xref ref-type="bibr" rid="bib12">Heinrich et al., 2014</xref>). This observation suggests that either AAV toxicity restrains the AtoN conversion process, or LV/RV boosts the AtoN conversion process in an unknown manner.</p><p>To exclude the potential toxicity of AAV, we adopted ASO as an alternative method for PTBP1 repression and found ASO-<italic>Ptbp1</italic> also failed to convert astrocytes into neurons or DAns. This result is inconsistent with that of a previous study claiming that AtoN conversion occurred after ASO-<italic>Ptbp1</italic> delivery (<xref ref-type="bibr" rid="bib30">Qian et al., 2020</xref>). However, we believe that their result is not convincing since the reporter mice-<italic>Rosa-Tdtomato</italic> (Ai14) used for lineage-tracing by <xref ref-type="bibr" rid="bib30">Qian et al., 2020</xref> has been questioned for occasional leakage to neurons (<xref ref-type="bibr" rid="bib45">Wang et al., 2021</xref>). Other possible reasons for the discrepancy may be different ASO-mediated PTBP1 repression efficiency, different lineage-tracing mouse types and genetic backgrounds, and different experimental time lengths.</p><p>The major weakness of the present study is that we only rule out the possibility of astrocyte conversion to neuron, including DAn using <italic>Aldh1l1</italic> promoter-based lineage-tracing mice. Whether other latent neurogenic cell types such as NSC (<xref ref-type="bibr" rid="bib24">Maimon et al., 2021</xref>), oligodendrocytes (<xref ref-type="bibr" rid="bib46">Weinberg et al., 2017</xref>), or NG2 glia, could be converted to neurons upon PTBP1 repression requires further investigation. Our results showed that ASO had no cell selectivity and could non-specifically enter different cell types to repress PTBP1 expression. These neurogenic cell types could be converted into neurons after PTBP1 repression Therefore, a reliable lineage-tracing method targeting these neurogenic cell types is necessary for future studies to identify the genuine cell identity that might contribute to neuron restoration.</p><p>One important question of the present study is whether and to what extent the reactive state of astrocytes in the 6-OHDA model could truly reflect the real state of astrocytes in PD patients. Acute lesions induced by neurotoxins, such as 6-OHDA, usually results in substantial neuron loss, creating an inflammatory microenvironment characterized by the presence of both A1 (pro-inflammatory) and A2 (anti-inflammatory) astrocyte subtypes (<xref ref-type="bibr" rid="bib34">Ryu et al., 2020</xref>). In contrast, as one of the most important risk factors for PD, normal aging induces pro-inflammatory A1 like astrocyte reactivity (<xref ref-type="bibr" rid="bib8">Clarke et al., 2018</xref>), which may accurately reflect the real state of PD patients. In particular, during ischemia stroke, a classic model characterized by the presence of A2 astrocytes, astrocytes spontaneously become neurogenic and the Notch pathway is repressed (<xref ref-type="bibr" rid="bib23">Magnusson et al., 2014</xref>). We therefore assume that pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), could be detrimental to the AtoN conversion process and the survival, maturation, and subsequent neurite outgrowth of the newborn neurons (<xref ref-type="bibr" rid="bib16">Karimi-Abdolrezaee and Billakanti, 2012</xref>; <xref ref-type="bibr" rid="bib2">Belenguer et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Park and Bowers, 2010</xref>), whereas the anti-inflammatory cytokines and neurotrophic factors, such as brain-derived neurotrophic factor might be beneficial and even critical (<xref ref-type="bibr" rid="bib26">Niu et al., 2013</xref>). Therefore, whether A2 astrocytes could be converted to neurons including DAns more efficiently, and more importantly, how to induce beneficial A2 astrocytes in the brains of PD patients for neural repair and regeneration needs further investigation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of University (Approval number: 2018–059). The protocol was reviewed and approved by the Ethics Committee on Laboratory Animal Care. The mice were housed in rooms with controlled 12 hr light/dark cycles, temperature, and humidity, and food and water were provided ad libitum. Eight- to 10-week-old C57BL/6 mice weighing 22–26 g were obtained from the Vital River Laboratory Animal Technological Company (Beijing, China). <italic>Aldh1l1-CreERT2</italic> transgenic mice (Stock number #029655), <italic>Rpl22 <sup>lsl-HA</sup></italic> (Ribotag) mice (Stock number #011029), and <italic>Rosa26<sup>lsl-YFP</sup></italic> mice (Stock number #006148) were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). <italic>Aldh1l1-CreERT2</italic> mice were used for breeding to the <italic>Rpl22<sup>lsl-HA</sup></italic> mice or <italic>Rosa26<sup>lsl-YFP</sup></italic> mice. Eight- to 10-week-old <italic>Aldh1l1-CreERT2;Rpl22<sup>lsl-HA</sup></italic> and <italic>Aldh1l1-CreERT2;Rosa26<sup>lsl-YFP</sup></italic> mice were used for lineage-tracing experiments.</p></sec><sec id="s4-2"><title>Tamoxifen (TAM) administration</title><p>The protocol of TAM administration was determined according to previous work (<xref ref-type="bibr" rid="bib38">Srinivasan et al., 2016</xref>) with little modifications. Briefly, TAM-free base (Sigma, Shanghai, China) was dissolved in corn oil (Aladdin, Shanghai, China) at a concentration of 10 mg/mL in a 60°C water bath for 30 mins. TAM was orally administered at a daily dose of 100 mg/kg body weight for 5 consecutive days. Experiments were performed 2 weeks after the last TAM administration.</p></sec><sec id="s4-3"><title>6-OHDA model</title><p>The procedure was based on previous study with minor modifications (<xref ref-type="bibr" rid="bib32">Rivetti di Val Cervo et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Qian et al., 2020</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2020</xref>). In brief, 6-OHDA (Sigma, Shanghai, China) was dissolved in ice-cold saline solution (0.9% NaCl) containing 0.2 mg/mL L-Ascorbic acid (BBI Life Sciences, Shanghai, China) at a concentration of 3 mg/mL. After anesthetized with 3% isoflurane, mice were then placed in a stereotaxic instrument (Model 940, Kopf Instruments, Tujunga, CA, USA) and delivered with 1 μL of 6-OHDA solution (3 μg) into the right medial forebrain bundle (mFB) at a speed of 100 nL/min according to the following coordinates: anteroposterior (A/P) = –1.20 mm, mediolateral (M/L) = 1.30 mm, dorsoventral (D/V) = –4.75 mm. Injections were conducted with a 10 μL syringe connected to a 33-Ga needle (Hamilton, Reno, NV, USA) using a microsyringe pump (KDS LegatoTM 130, Holliston, MA, USA). After 6-OHDA injection, mice were typically allowed to recover for 3 weeks with intense daily care.</p></sec><sec id="s4-4"><title>Apomorphine-induced rotation</title><p>Apomorphine-induced rotation was performed 3 weeks after 6-OHDA lesion and 3 months after AAVs delivery or 2 months after ASOs delivery. Briefly, 10 mins after intraperitoneal injection of apomorphine (Sigma-Aldrich, 5 mg/kg dissolved in ice-cold saline solution), each mouse was placed in an opaque cylinder (30 cm diameter) for free moving with a camera recording above for 20 mins as reported (<xref ref-type="bibr" rid="bib52">Zhou et al., 2020</xref>).</p></sec><sec id="s4-5"><title>AAV production and infection</title><p>To effectively repress astroglial PTBP1 in vivo, we designed and synthesized AAV (serotype 2/5) expressing EGFP, followed by shRNA targeting mouse <italic>Ptbp1</italic> (5ʹ-<named-content content-type="sequence">GGGTGAAGATCCTGTTCAATA</named-content>-3ʹ) as previously reported (<xref ref-type="bibr" rid="bib30">Qian et al., 2020</xref>), under the full-length (2.2 kb) <italic>GFAP</italic> (human glial fibrillary acidic protein) promoter (AAV2/5-<italic>GFAP</italic>-EGFP-5'miR-30a-shRNA(<italic>Ptbp1</italic>)–3'miR-30a-WPREs, AAV-sh<italic>Ptbp1</italic> for short, titer: 3.41E+12 vg/mL). The corresponding virus expressing scramble shRNA (same nucleotide composition but in a different sequence order) was used as a control (AAV2/5-<italic>GFAP</italic>-EGFP-5'miR-30a-shRNA(scramble)–3'miR-30a-WPREs, AAV-shscramble for short, titer: 2.57E+12 vg/mL) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Both AAVs were synthesized based on the pAAV-<italic>GFAP</italic>-EGFP-WPRE-hGH plasmid (Addgene #105549) and packaged by BrainVTA Co., Ltd (Wuhan, China).</p><p>Before injection into the mouse brain, the AAVs were adjusted to 1E+12 vg/mL using sterile Dulbecco’s phosphate buffered saline (DPBS, Gibco, Thermo Fisher Scientific, Inc, Waltham, MA, USA). Wildtype or lineage-tracing mice were subjected to AAV injection into the substantia nigra (1 μL) or striatum (2 μL), respectively, at a speed of 100 nL/min. The coordinates indicating distance from bregma were A/<italic>P</italic> = –2.90 mm, M/L = 1.30 mm, and D/V = –4.35 mm for the substantia nigra, and A/<italic>P</italic> = 0.80 mm, M/L = 1.60 mm, and D/V = –2.80 mm for the striatum. After injection, the needle remained in place for at least 5 mins to prevent retrograde flow along the needle track, and the needle was slowly removed from the mouse brain. Cleaning and suturing of the wound were performed after the needle was removed.</p></sec><sec id="s4-6"><title>Antisense oligonucleotides (ASOs) synthesis and delivery</title><p>ASOs were synthesized by Synbio Technology (Suzhou, China), the sequence and modification for ASO-<italic>Ptbp1</italic> (5ʹ-<named-content content-type="sequence">GTGGAAATATTGCTAGGCAC</named-content>-3ʹ) and control ASO (5ʹ-<named-content content-type="sequence">CCTATAGGACTATCCAGGAA</named-content>-3ʹ) were performed as reported (<xref ref-type="bibr" rid="bib24">Maimon et al., 2021</xref>). Briefly, 10 core 2ʹ-deoxyribonucleotides in the central were flanked on both 5ʹ and 3ʹ sides by 5 2ʹ-methoxyethyl (MOE)-modified nucleotides. The backbones of all ASOs contain phosphorothioate modifications and all cytosine residues were modified as 5ʹ-methylcytosines. Cyanine dye Cy3 was attached to the 3ʹ end of those ASOs for fluorescence detection. After dissolved in sterile and Rnase-free DPBS at a concentration of 1 μg/μL, ASOs were subpacked and stored at –80°C to avoid repeated freezing and thawing. A 2 μL of ASO was injected into the substantia nigra (A/<italic>P</italic> = –2.90 mm, M/L = 1.30 mm, and D/V = –4.35 mm) of astrocyte-specific lineage-tracing mice with or without 6-OHDA lesion.</p></sec><sec id="s4-7"><title>Immunofluorescent analysis</title><p>For immunofluorescent analysis, mice were anesthetized with 1.25% Avertin and were perfused intracardially with ice-cold phosphate buffered saline (PBS), followed by 4% paraformaldehyde (PFA, Sigma, China) in PBS at a flow rate of 10 mL/min. The brains were then removed and post-fixed in 4% PFA at 4°C overnight (8–12 hrs), followed by immersion in 20 and 30% sucrose for 24 hrs respectively. Immunofluorescent analysis was performed as previously described (<xref ref-type="bibr" rid="bib49">Yu et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Hu et al., 2019</xref>). In brief, cryostat-coronal sections encompassing the entire midbrain (20 μm) and striatum (30 μm) were serially collected. Free-floating sections were pre-incubated in blocking solution containing 5% normal donkey serum and 0.3% Triton X-100 in 50 mM Tris-buffered saline (pH = 7.4) at room temperature for 1 hr. Primary antibodies against HA tag (Rabbit, Abcam, ab9110, 1:1000), GFP (Rabbit, Abcam, ab290, 1:1000), GFP (Chicken, Abcam, ab13970, 1:1000), TH (Chicken, Millipore, AB9702, 1:1000), NeuN (Mouse IgG1, Millipore, MAB377, 1:1000), and PTBP1 (Rabbit, Invitrogen, PA5-81297, 1:1000) were dissolved in diluent and incubated with sections overnight at 4°C. After washing three times, sections were incubated with the secondary antibodies (Thermo Fisher or Jackson ImmunoResearch), which were conjugated with Alexa 488, Alexa 555, or Alexa 647 at room temperature for 1 hr. The sections were visualized under a confocal laser scanning microscope (LSM 780, Carl Zeiss, Germany) and captured in gray scale and pseudocolored for presentation. A 12 μm thick confocal Z-stack was acquired using ×63 objective. Three-dimensional reconstruction of z-stack images was generated using the Zeiss Zen software (blue edition).</p></sec><sec id="s4-8"><title>Immunoblot analysis</title><p>Two months after ASO-Ctrl or ASO-<italic>Ptbp1</italic> delivery, mouse midbrains were homogenized, lysed, and resolved using 10% SDS-PAGE, then transferred to a polyvinylidene difluoride (PVDF) membrane and probed with the primary antibodies (PTBP1, Rabbit, Invitrogen PA5-81297, 1:1000; β-actin, Mouse, Santa Cruz sc-47778, 1:5000) overnight at 4°C on a shaker. The secondary antibodies were horseradish peroxidase (HRP)-conjugated, and the signals were detected using ECL.</p></sec><sec id="s4-9"><title>Statistics</title><p>GraphPad Prism (GraphPad software, version 9.0) was used for the statistical analysis. All data are presented as mean ± SEM (standard error of the mean). When comparing data from two groups, a two-tailed Student’s t test was used. When there were two variables, ANOVA followed by Tukey’s multiple comparisons test was used. For all analyses, statistical significance was considered when probability value of p&lt;0.05.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were approved and performed in strict accordance with the guidelines by the Institutional Animal Care and Use Committee (IACUC) protocols (No.2018-059) of Sun Yat-Sen University, Guangzhou,China. The protocol was reviewed and approved by the Ethics Committee of Zhongshan School of Medicine(ZSSOM) on Laboratory Animal Care(Permit number: SYSU-IACUC-2018-059). All surgery was performed under isoflurane anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-75636-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; source data files have been provided for all the figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Qingxing Zhang for his assistance with the animal breeding and genotyping. This study was supported by grants from the National Key R&amp;D Program of China (2018YFA0108300), the National Natural Science Foundation of China (U1801681, 81771368, 31871019, 32070959), the Key Realm R&amp;D Program of Guangdong Province (2018B030337001), the Guangdong Provincial Key Laboratory of Brain Function and Disease (2020B1212060024).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arenas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Method to combat Parkinson’s disease by astrocyte-to-neuron conversion</article-title><source>Nature</source><volume>582</volume><fpage>489</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-01817-4</pub-id><pub-id pub-id-type="pmid">32581373</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belenguer</surname><given-names>G</given-names></name><name><surname>Duart-Abadia</surname><given-names>P</given-names></name><name><surname>Jordán-Pla</surname><given-names>A</given-names></name><name><surname>Domingo-Muelas</surname><given-names>A</given-names></name><name><surname>Blasco-Chamarro</surname><given-names>L</given-names></name><name><surname>Ferrón</surname><given-names>SR</given-names></name><name><surname>Morante-Redolat</surname><given-names>JM</given-names></name><name><surname>Fariñas</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Adult Neural Stem Cells Are Alerted by Systemic Inflammation through TNF-α Receptor Signaling</article-title><source>Cell Stem Cell</source><volume>28</volume><fpage>285</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.10.016</pub-id><pub-id pub-id-type="pmid">33207218</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Blackshaw</surname><given-names>S</given-names></name><name><surname>Hoang</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Appel</surname><given-names>H</given-names></name><name><surname>Pannullo</surname><given-names>N</given-names></name><name><surname>Ozawa</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Peachey</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ptbp1 Deletion Does Not Induce Glia-to-Neuron Conversion in Adult Mouse Retina and Brain</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.10.04.462784</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brulet</surname><given-names>R</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Miranda</surname><given-names>C</given-names></name><name><surname>Giacca</surname><given-names>M</given-names></name><name><surname>Kaspar</surname><given-names>BK</given-names></name><name><surname>Nakashima</surname><given-names>K</given-names></name><name><surname>Hsieh</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>NEUROD1 Instructs Neuronal Conversion in Non-Reactive Astrocytes</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>1506</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.04.013</pub-id><pub-id pub-id-type="pmid">28506534</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffo</surname><given-names>A</given-names></name><name><surname>Vosko</surname><given-names>MR</given-names></name><name><surname>Ertürk</surname><given-names>D</given-names></name><name><surname>Hamann</surname><given-names>GF</given-names></name><name><surname>Jucker</surname><given-names>M</given-names></name><name><surname>Rowitch</surname><given-names>D</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair</article-title><source>PNAS</source><volume>102</volume><fpage>18183</fpage><lpage>18188</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506535102</pub-id><pub-id pub-id-type="pmid">16330768</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffo</surname><given-names>A</given-names></name><name><surname>Rite</surname><given-names>I</given-names></name><name><surname>Tripathi</surname><given-names>P</given-names></name><name><surname>Lepier</surname><given-names>A</given-names></name><name><surname>Colak</surname><given-names>D</given-names></name><name><surname>Horn</surname><given-names>AP</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain</article-title><source>PNAS</source><volume>105</volume><fpage>3581</fpage><lpage>3586</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709002105</pub-id><pub-id pub-id-type="pmid">18299565</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Ma</surname><given-names>NX</given-names></name><name><surname>Pei</surname><given-names>ZF</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Do-Monte</surname><given-names>FH</given-names></name><name><surname>Keefe</surname><given-names>S</given-names></name><name><surname>Yellin</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>MS</given-names></name><name><surname>Yin</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Minier-Toribio</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Quirk</surname><given-names>GJ</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair after Ischemic Injury through In Vivo Astrocyte-to-Neuron Conversion</article-title><source>Molecular Therapy</source><volume>28</volume><fpage>217</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.09.003</pub-id><pub-id pub-id-type="pmid">31551137</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>LE</given-names></name><name><surname>Liddelow</surname><given-names>SA</given-names></name><name><surname>Chakraborty</surname><given-names>C</given-names></name><name><surname>Münch</surname><given-names>AE</given-names></name><name><surname>Heiman</surname><given-names>M</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Normal aging induces A1-like astrocyte reactivity</article-title><source>PNAS</source><volume>115</volume><fpage>E1896</fpage><lpage>E1905</lpage><pub-id pub-id-type="doi">10.1073/pnas.1800165115</pub-id><pub-id pub-id-type="pmid">29437957</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gascón</surname><given-names>S</given-names></name><name><surname>Murenu</surname><given-names>E</given-names></name><name><surname>Masserdotti</surname><given-names>G</given-names></name><name><surname>Ortega</surname><given-names>F</given-names></name><name><surname>Russo</surname><given-names>GL</given-names></name><name><surname>Petrik</surname><given-names>D</given-names></name><name><surname>Deshpande</surname><given-names>A</given-names></name><name><surname>Heinrich</surname><given-names>C</given-names></name><name><surname>Karow</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>SP</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Beckers</surname><given-names>J</given-names></name><name><surname>Irmler</surname><given-names>M</given-names></name><name><surname>Berndt</surname><given-names>C</given-names></name><name><surname>Angeli</surname><given-names>JPF</given-names></name><name><surname>Conrad</surname><given-names>M</given-names></name><name><surname>Berninger</surname><given-names>B</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification and Successful Negotiation of a Metabolic Checkpoint in Direct Neuronal Reprogramming</article-title><source>Cell Stem Cell</source><volume>18</volume><fpage>396</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.12.003</pub-id><pub-id pub-id-type="pmid">26748418</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grande</surname><given-names>A</given-names></name><name><surname>Sumiyoshi</surname><given-names>K</given-names></name><name><surname>López-Juárez</surname><given-names>A</given-names></name><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Sakthivel</surname><given-names>B</given-names></name><name><surname>Aronow</surname><given-names>B</given-names></name><name><surname>Campbell</surname><given-names>K</given-names></name><name><surname>Nakafuku</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Environmental impact on direct neuronal reprogramming in vivo in the adult brain</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2373</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3373</pub-id><pub-id pub-id-type="pmid">23974433</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model</article-title><source>Cell Stem Cell</source><volume>14</volume><fpage>188</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.12.001</pub-id><pub-id pub-id-type="pmid">24360883</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>C</given-names></name><name><surname>Bergami</surname><given-names>M</given-names></name><name><surname>Gascón</surname><given-names>S</given-names></name><name><surname>Lepier</surname><given-names>A</given-names></name><name><surname>Viganò</surname><given-names>F</given-names></name><name><surname>Dimou</surname><given-names>L</given-names></name><name><surname>Sutor</surname><given-names>B</given-names></name><name><surname>Berninger</surname><given-names>B</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sox2-mediated conversion of NG2 glia into induced neurons in the injured adult cerebral cortex</article-title><source>Stem Cell Reports</source><volume>3</volume><fpage>1000</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2014.10.007</pub-id><pub-id pub-id-type="pmid">25458895</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>c-Jun/Bim Upregulation in Dopaminergic Neurons Promotes Neurodegeneration in the MPTP Mouse Model of Parkinson’s Disease</article-title><source>Neuroscience</source><volume>399</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2018.12.026</pub-id><pub-id pub-id-type="pmid">30590105</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting PTB as a One-Step Procedure for In Situ Astrocyte-to-Dopamine Neuron Reprogramming in Parkinson’s Disease</article-title><source>Neuroscience Bulletin</source><volume>37</volume><fpage>430</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1007/s12264-021-00630-x</pub-id><pub-id pub-id-type="pmid">33439451</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>S</given-names></name><name><surname>Parylak</surname><given-names>SL</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Mac</surname><given-names>N</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Gallina</surname><given-names>I</given-names></name><name><surname>Bloyd</surname><given-names>C</given-names></name><name><surname>Newberry</surname><given-names>A</given-names></name><name><surname>Saavedra</surname><given-names>CD</given-names></name><name><surname>Novak</surname><given-names>O</given-names></name><name><surname>Gonçalves</surname><given-names>JT</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Shtrahman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>AAV ablates neurogenesis in the adult murine hippocampus</article-title><source>eLife</source><volume>10</volume><elocation-id>e59291</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.59291</pub-id><pub-id pub-id-type="pmid">34259630</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi-Abdolrezaee</surname><given-names>S</given-names></name><name><surname>Billakanti</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects</article-title><source>Molecular Neurobiology</source><volume>46</volume><fpage>251</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1007/s12035-012-8287-4</pub-id><pub-id pub-id-type="pmid">22684804</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kretzschmar</surname><given-names>K</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Lineage tracing</article-title><source>Cell</source><volume>148</volume><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.002</pub-id><pub-id pub-id-type="pmid">22265400</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>M</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>NeuroD1 overexpression in spinal neurons accelerates axonal regeneration after sciatic nerve injury</article-title><source>Experimental Neurology</source><volume>327</volume><elocation-id>113215</elocation-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2020.113215</pub-id><pub-id pub-id-type="pmid">31991126</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leib</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Monteys</surname><given-names>AM</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Limited astrocyte-to-neuron conversion in the mouse brain using NeuroD1 overexpression</article-title><source>Molecular Therapy</source><volume>30</volume><fpage>982</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2022.01.028</pub-id><pub-id pub-id-type="pmid">35123657</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentini</surname><given-names>C</given-names></name><name><surname>d’Orange</surname><given-names>M</given-names></name><name><surname>Marichal</surname><given-names>N</given-names></name><name><surname>Trottmann</surname><given-names>M-M</given-names></name><name><surname>Vignoles</surname><given-names>R</given-names></name><name><surname>Foucault</surname><given-names>L</given-names></name><name><surname>Verrier</surname><given-names>C</given-names></name><name><surname>Massera</surname><given-names>C</given-names></name><name><surname>Raineteau</surname><given-names>O</given-names></name><name><surname>Conzelmann</surname><given-names>K-K</given-names></name><name><surname>Rival-Gervier</surname><given-names>S</given-names></name><name><surname>Depaulis</surname><given-names>A</given-names></name><name><surname>Berninger</surname><given-names>B</given-names></name><name><surname>Heinrich</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reprogramming reactive glia into interneurons reduces chronic seizure activity in a mouse model of mesial temporal lobe epilepsy</article-title><source>Cell Stem Cell</source><volume>28</volume><fpage>2104</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2021.09.002</pub-id><pub-id pub-id-type="pmid">34592167</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Miao</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ascl1 Converts Dorsal Midbrain Astrocytes into Functional Neurons In Vivo</article-title><source>The Journal of Neuroscience</source><volume>35</volume><fpage>9336</fpage><lpage>9355</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3975-14.2015</pub-id><pub-id pub-id-type="pmid">26109658</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MH</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>YG</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Differential neuronal reprogramming induced by NeuroD1 from astrocytes in grey matter <italic>versus</italic> white matter</article-title><source>Neural Regeneration Research</source><volume>15</volume><fpage>342</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.265185</pub-id><pub-id pub-id-type="pmid">31552908</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnusson</surname><given-names>JP</given-names></name><name><surname>Göritz</surname><given-names>C</given-names></name><name><surname>Tatarishvili</surname><given-names>J</given-names></name><name><surname>Dias</surname><given-names>DO</given-names></name><name><surname>Smith</surname><given-names>EMK</given-names></name><name><surname>Lindvall</surname><given-names>O</given-names></name><name><surname>Kokaia</surname><given-names>Z</given-names></name><name><surname>Frisén</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse</article-title><source>Science (New York, N.Y.)</source><volume>346</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1126/science.346.6206.237</pub-id><pub-id pub-id-type="pmid">25301628</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maimon</surname><given-names>R</given-names></name><name><surname>Chillon-Marinas</surname><given-names>C</given-names></name><name><surname>Snethlage</surname><given-names>CE</given-names></name><name><surname>Singhal</surname><given-names>SM</given-names></name><name><surname>McAlonis-Downes</surname><given-names>M</given-names></name><name><surname>Ling</surname><given-names>K</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Da Cruz</surname><given-names>S</given-names></name><name><surname>Hnasko</surname><given-names>TS</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Therapeutically viable generation of neurons with antisense oligonucleotide suppression of PTB</article-title><source>Nature Neuroscience</source><volume>24</volume><fpage>1089</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1038/s41593-021-00864-y</pub-id><pub-id pub-id-type="pmid">34083786</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattugini</surname><given-names>N</given-names></name><name><surname>Bocchi</surname><given-names>R</given-names></name><name><surname>Scheuss</surname><given-names>V</given-names></name><name><surname>Russo</surname><given-names>GL</given-names></name><name><surname>Torper</surname><given-names>O</given-names></name><name><surname>Lao</surname><given-names>CL</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inducing Different Neuronal Subtypes from Astrocytes in the Injured Mouse Cerebral Cortex</article-title><source>Neuron</source><volume>103</volume><fpage>1086</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.08.009</pub-id><pub-id pub-id-type="pmid">31488328</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>T</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>DK</given-names></name><name><surname>Bachoo</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>In vivo reprogramming of astrocytes to neuroblasts in the adult brain</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>1164</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1038/ncb2843</pub-id><pub-id pub-id-type="pmid">24056302</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>DK</given-names></name><name><surname>Vue</surname><given-names>TY</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Bachoo</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>JE</given-names></name><name><surname>Zhang</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SOX2 reprograms resident astrocytes into neural progenitors in the adult brain</article-title><source>Stem Cell Reports</source><volume>4</volume><fpage>780</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.03.006</pub-id><pub-id pub-id-type="pmid">25921813</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KM</given-names></name><name><surname>Bowers</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction</article-title><source>Cellular Signalling</source><volume>22</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2010.01.010</pub-id><pub-id pub-id-type="pmid">20096353</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Birtele</surname><given-names>M</given-names></name><name><surname>Shrigley</surname><given-names>S</given-names></name><name><surname>Benitez</surname><given-names>JA</given-names></name><name><surname>Hedlund</surname><given-names>E</given-names></name><name><surname>Parmar</surname><given-names>M</given-names></name><name><surname>Ottosson</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Direct Reprogramming of Resident NG2 Glia into Neurons with Properties of Fast-Spiking Parvalbumin-Containing Interneurons</article-title><source>Stem Cell Reports</source><volume>9</volume><fpage>742</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.07.023</pub-id><pub-id pub-id-type="pmid">28844658</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Maimon</surname><given-names>R</given-names></name><name><surname>Dowdy</surname><given-names>SF</given-names></name><name><surname>Devaraj</surname><given-names>NK</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Mobley</surname><given-names>WC</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name><name><surname>Fu</surname><given-names>XD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reversing a model of Parkinson’s disease with in situ converted nigral neurons</article-title><source>Nature</source><volume>582</volume><fpage>550</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2388-4</pub-id><pub-id pub-id-type="pmid">32581380</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Zhou</surname><given-names>FQ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>In vivo glial trans-differentiation for neuronal replacement and functional recovery in central nervous system</article-title><source>The FEBS Journal</source><volume>288</volume><fpage>4773</fpage><lpage>4785</lpage><pub-id pub-id-type="doi">10.1111/febs.15681</pub-id><pub-id pub-id-type="pmid">33351267</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivetti di Val Cervo</surname><given-names>P</given-names></name><name><surname>Romanov</surname><given-names>RA</given-names></name><name><surname>Spigolon</surname><given-names>G</given-names></name><name><surname>Masini</surname><given-names>D</given-names></name><name><surname>Martín-Montañez</surname><given-names>E</given-names></name><name><surname>Toledo</surname><given-names>EM</given-names></name><name><surname>La Manno</surname><given-names>G</given-names></name><name><surname>Feyder</surname><given-names>M</given-names></name><name><surname>Pifl</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>YH</given-names></name><name><surname>Sánchez</surname><given-names>SP</given-names></name><name><surname>Linnarsson</surname><given-names>S</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Harkany</surname><given-names>T</given-names></name><name><surname>Fisone</surname><given-names>G</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model</article-title><source>Nature Biotechnology</source><volume>35</volume><fpage>444</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/nbt.3835</pub-id><pub-id pub-id-type="pmid">28398344</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robel</surname><given-names>S</given-names></name><name><surname>Berninger</surname><given-names>B</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The stem cell potential of glia: lessons from reactive gliosis</article-title><source>Nature Reviews. Neuroscience</source><volume>12</volume><fpage>88</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nrn2978</pub-id><pub-id pub-id-type="pmid">21248788</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>YK</given-names></name><name><surname>Go</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>HY</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Seo</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Rhee</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>TG</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Metformin regulates astrocyte reactivity in Parkinson’s disease and normal aging</article-title><source>Neuropharmacology</source><volume>175</volume><elocation-id>108173</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108173</pub-id><pub-id pub-id-type="pmid">32497590</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>DR</given-names></name><name><surname>McKnight</surname><given-names>GS</given-names></name><name><surname>Amieux</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cell-type-specific isolation of ribosome-associated mRNA from complex tissues</article-title><source>PNAS</source><volume>106</volume><fpage>13939</fpage><lpage>13944</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907143106</pub-id><pub-id pub-id-type="pmid">19666516</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>IS</given-names></name><name><surname>LeComte</surname><given-names>MD</given-names></name><name><surname>Granger</surname><given-names>JC</given-names></name><name><surname>Quinlan</surname><given-names>NJ</given-names></name><name><surname>Spees</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Self-renewal and differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from the cortical peri-infarct area after stroke</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>7926</fpage><lpage>7940</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4303-11.2012</pub-id><pub-id pub-id-type="pmid">22674268</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirko</surname><given-names>S</given-names></name><name><surname>Behrendt</surname><given-names>G</given-names></name><name><surname>Johansson</surname><given-names>PA</given-names></name><name><surname>Tripathi</surname><given-names>P</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Bek</surname><given-names>S</given-names></name><name><surname>Heinrich</surname><given-names>C</given-names></name><name><surname>Tiedt</surname><given-names>S</given-names></name><name><surname>Colak</surname><given-names>D</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>IR</given-names></name><name><surname>Plesnila</surname><given-names>N</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Snapyan</surname><given-names>M</given-names></name><name><surname>Saghatelyan</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>LH</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Grobe</surname><given-names>K</given-names></name><name><surname>Dimou</surname><given-names>L</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog</article-title><source>Cell Stem Cell</source><volume>12</volume><fpage>426</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.01.019</pub-id><pub-id pub-id-type="pmid">23561443</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>TY</given-names></name><name><surname>Chai</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>BS</given-names></name><name><surname>Golshani</surname><given-names>P</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Khakh</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo</article-title><source>Neuron</source><volume>92</volume><fpage>1181</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.11.030</pub-id><pub-id pub-id-type="pmid">27939582</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Niu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>ML</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In vivo conversion of astrocytes to neurons in the injured adult spinal cord</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>3338</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4338</pub-id><pub-id pub-id-type="pmid">24569435</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torper</surname><given-names>O</given-names></name><name><surname>Pfisterer</surname><given-names>U</given-names></name><name><surname>Wolf</surname><given-names>DA</given-names></name><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>S</given-names></name><name><surname>Jakobsson</surname><given-names>J</given-names></name><name><surname>Björklund</surname><given-names>A</given-names></name><name><surname>Grealish</surname><given-names>S</given-names></name><name><surname>Parmar</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Generation of induced neurons via direct conversion in vivo</article-title><source>PNAS</source><volume>110</volume><fpage>7038</fpage><lpage>7043</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303829110</pub-id><pub-id pub-id-type="pmid">23530235</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torper</surname><given-names>O</given-names></name><name><surname>Ottosson</surname><given-names>DR</given-names></name><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>S</given-names></name><name><surname>Cardoso</surname><given-names>T</given-names></name><name><surname>Grealish</surname><given-names>S</given-names></name><name><surname>Parmar</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>In Vivo Reprogramming of Striatal NG2 Glia into Functional Neurons that Integrate into Local Host Circuitry</article-title><source>Cell Reports</source><volume>12</volume><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.06.040</pub-id><pub-id pub-id-type="pmid">26166567</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torper</surname><given-names>O</given-names></name><name><surname>Götz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Brain repair from intrinsic cell sources: Turning reactive glia into neurons</article-title><source>Progress in Brain Research</source><volume>230</volume><fpage>69</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/bs.pbr.2016.12.010</pub-id><pub-id pub-id-type="pmid">28552236</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>XF</given-names></name><name><surname>Vojtek</surname><given-names>A</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Retinal injury, growth factors, and cytokines converge on β-catenin and pStat3 signaling to stimulate retina regeneration</article-title><source>Cell Reports</source><volume>9</volume><fpage>285</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.08.048</pub-id><pub-id pub-id-type="pmid">25263555</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Tai</surname><given-names>W</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>XM</given-names></name><name><surname>Zhang</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The p53 Pathway Controls SOX2-Mediated Reprogramming in the Adult Mouse Spinal Cord</article-title><source>Cell Reports</source><volume>17</volume><fpage>891</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.038</pub-id><pub-id pub-id-type="pmid">27732862</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Serrano</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Revisiting astrocyte to neuron conversion with lineage tracing in vivo</article-title><source>Cell</source><volume>184</volume><fpage>5465</fpage><lpage>5481</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.005</pub-id><pub-id pub-id-type="pmid">34582787</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>MS</given-names></name><name><surname>Criswell</surname><given-names>HE</given-names></name><name><surname>Powell</surname><given-names>SK</given-names></name><name><surname>Bhatt</surname><given-names>AP</given-names></name><name><surname>McCown</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Viral Vector Reprogramming of Adult Resident Striatal Oligodendrocytes into Functional Neurons</article-title><source>Molecular Therapy</source><volume>25</volume><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.01.016</pub-id><pub-id pub-id-type="pmid">28202388</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Parry</surname><given-names>M</given-names></name><name><surname>Hou</surname><given-names>XY</given-names></name><name><surname>Liu</surname><given-names>MH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Cain</surname><given-names>R</given-names></name><name><surname>Pei</surname><given-names>ZF</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Guo</surname><given-names>ZY</given-names></name><name><surname>Abhijeet</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington’s disease</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1105</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14855-3</pub-id><pub-id pub-id-type="pmid">32107381</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lei</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lineage tracing of direct astrocyte-to-neuron conversion in the mouse cortex</article-title><source>Neural Regeneration Research</source><volume>16</volume><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.295925</pub-id><pub-id pub-id-type="pmid">33063738</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson’s disease</article-title><source>Experimental Neurology</source><volume>302</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2018.01.009</pub-id><pub-id pub-id-type="pmid">29337144</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Cananzi</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name><name><surname>Hon</surname><given-names>GC</given-names></name><name><surname>Zhang</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A single factor elicits multilineage reprogramming of astrocytes in the adult mouse striatum</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2107339119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2107339119</pub-id><pub-id pub-id-type="pmid">35254903</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Qi</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neuroregenerative gene therapy to treat temporal lobe epilepsy in a rat model</article-title><source>Progress in Neurobiology</source><volume>208</volume><elocation-id>102198</elocation-id><pub-id pub-id-type="doi">10.1016/j.pneurobio.2021.102198</pub-id><pub-id pub-id-type="pmid">34852273</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice</article-title><source>Cell</source><volume>181</volume><fpage>590</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.024</pub-id><pub-id pub-id-type="pmid">32272060</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75636.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Przedborski</surname><given-names>Serge</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01esghr10</institution-id><institution>Columbia University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.11.12.468309" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.12.468309"/></front-stub><body><p>In aggregate, we believe that this study provides important new light on the role of PTB1 repression as a potential therapeutic repair strategy. This paper elegantly utilizes a broad array of approaches to demonstrate, in a toxin-based mouse model of Parkinson's disease, that reactive astrocytes fail to convert into neurons such as dopaminergic neurons in brain areas specifically affected in this common neurodegenerative disorder (i.e. the striatum and the substantia nigra) upon repression of the RNA-binding protein PTB1. This finding is of enormous importance since previous studies have reported the reverse, namely that astrocytes can be converted into dopaminergic neurons in response to the repression of PTB1 and have used these results to propose that inhibition of PTB1 by gene therapy could represent new repair strategies for patients with disorders of the nervous system, such as Parkinson’s disease.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75636.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Przedborski</surname><given-names>Serge</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01esghr10</institution-id><institution>Columbia University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Berninger</surname><given-names>Benedikt</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.12.468309">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.11.12.468309v2">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Repressing PTBP1 is incapable to convert reactive astrocytes to dopaminergic neurons in a mouse model of Parkinson's disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Suzanne Pfeffer as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Benedikt Berninger (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>All three reviewers expressed a high level of enthusiasm for your work and made important comments/recommendations (see appended reviews) that are, for the most part, straightforward and aimed at strengthening your study. Thus, we would like to see these being addressed before your manuscript can be considered suitable for publication. Moreover, we would like you to also consider the following revisions:</p><p>(1) To tone-down your findings throughout including in the title as it was felt that you overstate the implications of this work given the fact that clearly, 6-OHDA does not capture the etiology of PD and that your data leave open the possibility that modulation of ptbp1 could facilitate dopaminergic neurogenesis if tested in other models, by other techniques, over longer time scales, or in greater Ns.</p><p>(2) To edit the presentation of the statistics as mentioned by Reviewer #1 throughout.</p><p>(3) to revise your discussion. Indeed, we concur with the Reviewers that a more formal discussion would increase the potential impact of your work. In particular, it would be important that the discussion better covers the limitations of the present work and stresses the outstanding questions.</p><p>Accordingly, we would recommend that you discuss at least the following two points:</p><p>(1) the acute nature of the 6-OHDA model and whether this may elicit cellular alterations, including in astrocytes, distinct from those that may arise in a chronic neurodegenerative process; and</p><p>(2) whether AAVs themselves could prevent neuronal conversion as suggested by Johnston et al., (<italic>eLife</italic> 2021). Although we recognize that many studies claiming successful glia-to-neuron conversion have used 6-OHDA and AAVs, we believe that you should discuss the possibility that other models of PD (as already mentioned above) and/or other approaches of knocking down Ptbp1, could potentially yield positive results. For instance, Maimon et al., (Nat Neurosci 2021) used antisense oligonucleotides against Ptbp1 to observe increased neurogenesis in the dentate gyrus, but not so markedly in other brain areas.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>This is a very strong, elegant and straightforward study designed to test the question as to whether compared to quiescent astrocytes, reactive astrocytes may be more amendable to be converted into neurons, and specifically, dopaminergic neurons upon repression of PTB1. As a first step, the authors show that a number of neurons, including dopaminergic neurons, did express GFP in the substantia nigra of mice after injection of AAV-Gfap-EGFP-shPtb1. However, upon combining an elegant lineage tracing method, the authors found no evidence of GFP/NeuN or GFP/TH neurons derived from HA labeled astrocytes in both intact and 6-OHDA lesioned mice. In the latter the authors showed data in support of the reactive state of astrocytes. In light of this data, Chen and collaborators concluded that, in mice, there is no evidence of quiescent or reactive astrocyte conversion into dopaminergic neurons upon repression of PTB1.</p><p>This is a very convincing study, extremely well designed and conducted, and shows a set of striking data. The methods are excellent, and the results are well presented and discussed.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Considering the following points might improve the manuscript</p><p>1. It would be useful to show which cells were targeted by the AAV construct at earlier time points, e.g. 7days following infection. There is a general agreement that hGFAP promoter may be leaky and a tighter system would use AAVs with floxed transgenes. However, even if the system lacks in specificity, the authors do show convincingly that Ptbp1 is knocked down in astrocytes. This effect, illustrated in Figure 1B should be quantified.</p><p>2. In Figure 1C, the authors should provide 3D visualization of individual neurons to demonstrate co-localization of GFP with NeuN or TH more clearly.</p><p>3. The authors should quantitatively compare the number of NeuN and TH positive neurons in w/o 6-OHDA controls to those following scramble or Ptbp1 knockdown treatment in figure 3.</p><p>4. Given that the authors suspect that AAV-mediated GFP expression occurs in neurons despite being driven from hGAP promoter, would it make sense to show presence of GFP mRNA in neurons, even if very little, at an time point when GFP fluorescence is still undetectable in neurons but clearly seen in astrocytes? The authors could use RNA Scope towards this. I would expect to see clear signs of low-level expression compared to massive expression in astrocytes.</p><p>5. Given that hGFAP driven expression should eventually cease when astrocytes convert, would this have any impact on the interpretation? The authors should analyze whether there are any fate-mapped neurons that seem to lack AAV-mediated GFP expression. Or do the AAV constructs used in Figure 3 lack GFP to allow for TH IF?</p><p>6. The left panels in 3B must be controls, but this is not clearly indicated in the figure legend.</p><p>7. English should be revised.</p><p>8. Regarding the ethical endorsement of animal experiments, more clear information regarding the endorsing body should be provided. Only &quot;university&quot; is mentioned (Care and Use committee of university). Is there any legal number associated to this endorsement?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Chen et al., highlight a technical confound in previous publications that claim attenuation of PTBP1 results in trans-differentiation of astrocytes into dopamine neurons. While they clearly observe that previous use of recombinant AAV vectors lead to EGFP expression in dopaminergic neurons despite using an astrocyte &quot;specific&quot; promoter, the authors cannot conclude from the presented experiments that attenuation of PTBP1 does not achieve trans-differentiation. This is because the use of AAV could render astrocytes unable to differentiate into dopaminergic neurons in response to successful downregulation of PTBP1. Adding other, AAV independent, means of achieving PTBP1 downregulation in astrocytes in vivo would strengthen this study.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75636.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>All three reviewers expressed a high level of enthusiasm for your work and made important comments/recommendations (see appended reviews) that are, for the most part, straightforward and aimed at strengthening your study. Thus, we would like to see these being addressed before your manuscript can be considered suitable for publication. Moreover, we would like you to also consider the following revisions:</p><p>(1) to tone-down your findings throughout including in the title as it was felt that you overstate the implications of this work given the fact that clearly, 6-OHDA does not capture the etiology of PD and that your data leave open the possibility that modulation of ptbp1 could facilitate dopaminergic neurogenesis if tested in other models, by other techniques, over longer time scales, or in greater Ns.</p></disp-quote><p>We appreciate the editor’s suggestion and have revised our title to ‘Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a mouse 6-hydroxydopamine model of Parkinson's disease’.</p><disp-quote content-type="editor-comment"><p>(2) To edit the presentation of the statistics as mentioned by Reviewer #1 throughout.</p></disp-quote><p>The detailed statistical information is provided in our revised manuscript.</p><disp-quote content-type="editor-comment"><p>(3) to revise your discussion. Indeed, we concur with the Reviewers that a more formal discussion would increase the potential impact of your work. In particular, it would be important that the discussion better covers the limitations of the present work and stresses the outstanding questions.</p></disp-quote><p>As suggested by the editor and reviewers, we have added a formal discussion in our revised manuscript that covers the limitations of the present work and the outstanding questions in this field.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Considering the following points might improve the manuscript</p><p>1. It would be useful to show which cells were targeted by the AAV construct at earlier time points, e.g. 7days following infection. There is a general agreement that hGFAP promoter may be leaky and a tighter system would use AAVs with floxed transgenes. However, even if the system lacks in specificity, the authors do show convincingly that Ptbp1 is knocked down in astrocytes. This effect, illustrated in Figure 1B should be quantified.</p></disp-quote><p>To identify the exact cell type targeted by our AAV construct seven days after AAV infection, we performed immunostaining and GFP<sup>+</sup> cell number counting in the substantia nigra and striatum, respectively. The results showed that most of the infected cells were astrocytes (AldoC<sup>+</sup>), and a few other cells, such as neurons (NeuN<sup>+</sup>), NG2-glia (NG2<sup>+</sup>), and microglia (Iba-1<sup>+</sup>), were infected (Figure 1—figure supplement 1).</p><p>Moreover, as suggested by the reviewer, we have quantified the PTBP1 knockdown efficiency in Figure 1B, and the quantified data are included in the revised manuscript (Figure 1C).</p><disp-quote content-type="editor-comment"><p>2. In Figure 1C, the authors should provide 3D visualization of individual neurons to demonstrate co-localization of GFP with NeuN or TH more clearly.</p></disp-quote><p>To more clearly demonstrate the colocalization of GFP with NeuN or TH, we performed immunofluorescence experiments using anti-GFP, anti-TH, and anti-NeuN antibodies. Images were captured using a LSM780 confocal microscope (Zeiss). The enlarged 3D reconstruction of boxed individual neurons are shown in the lower panel of Figure 1D, F in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>3. The authors should quantitatively compare the number of NeuN and TH positive neurons in w/o 6-OHDA controls to those following scramble or Ptbp1 knockdown treatment in figure 3.</p></disp-quote><p>As suggested by the reviewer, we have quantified the number of NeuN<sup>+</sup> neurons and TH<sup>+</sup> dopaminergic neurons in the substantia nigra before and after AAV-sh<italic>Ptbp1</italic> or AAV-shscramble delivery in the 6-OHDA model and found no significant difference between the two groups, indicating that no neurons, including DA neurons, were regenerated in the substantia nigra after astroglial PTBP1 repression (Figure 3D, E).</p><disp-quote content-type="editor-comment"><p>4. Given that the authors suspect that AAV-mediated GFP expression occurs in neurons despite being driven from hGAP promoter, would it make sense to show presence of GFP mRNA in neurons, even if very little, at an time point when GFP fluorescence is still undetectable in neurons but clearly seen in astrocytes? The authors could use RNA Scope towards this. I would expect to see clear signs of low-level expression compared to massive expression in astrocytes.</p></disp-quote><p>We agree with the reviewer that low levels of GFP mRNA may appear in neurons at early time points, and we did observe low GFP protein levels in neurons 1 month after AAV-sh<italic>Ptbp1</italic> delivery, but not AAV-shscramble (Figure 1 D, F). According to a recent study, the coding sequence of some proneural genes, such as <italic>Neurod1</italic> could activate <italic>hGfap</italic> promoter via binding to cis-acting elements of the promoter in neurons (Wang et al., 2021). Therefore, we suppose that the shRNA sequence targeting <italic>Ptbp1</italic> per se might function similar to <italic>Neurod1</italic>, activating the <italic>hGfap</italic> promoter to drive GFP expression in neurons at a relatively low level.</p><disp-quote content-type="editor-comment"><p>5. Given that hGFAP driven expression should eventually cease when astrocytes convert, would this have any impact on the interpretation? The authors should analyze whether there are any fate-mapped neurons that seem to lack AAV-mediated GFP expression. Or do the AAV constructs used in Figure 3 lack GFP to allow for TH IF?</p></disp-quote><p>We understand the reviewer’s concern. Because the <italic>hGfap</italic> promoter activity gradually ceased during AtoN conversion, we chose <italic>Rpl22<sup>HA/HA</sup></italic> reporter mice to permanently label astrocytes with HA-tag. If AtoN conversion occurrs, astrocyte-derived neurons or dopaminergic neurons should be marked with HA. However, we did not detect any HA<sup>+</sup>NeuN<sup>+</sup> or HA<sup>+</sup>TH<sup>+</sup> cells after PTBP1 repression, suggesting that no neurons or DAn were converted from astrocytes.</p><p>The two AAV constructs used in this study were attached to EGFP driven by the <italic>hGfap</italic> promoter as illustrated in Figure 1A. We apologize for the misleading comment because GFP images were not provided, which have been included in the revised manuscript (Figure 3C). The fluorescence images in the manuscript were captured on a gray scale and pseudocolored for overlay presentation.</p><disp-quote content-type="editor-comment"><p>6. The left panels in 3B must be controls, but this is not clearly indicated in the figure legend.</p></disp-quote><p>We appreciate the reviewer’s reminder and have revised according to reviewer’s suggestion.</p><disp-quote content-type="editor-comment"><p>7. English should be revised.</p></disp-quote><p>As suggested by the reviewer, we have sent our manuscript to the Editage (www.editage.cn) for English language editing.</p><disp-quote content-type="editor-comment"><p>8. Regarding the ethical endorsement of animal experiments, more clear information regarding the endorsing body should be provided. Only &quot;university&quot; is mentioned (Care and Use committee of university). Is there any legal number associated to this endorsement?</p></disp-quote><p>We supplied detailed ethical endorsement information of animal experiments including permission numbers in the Animal part of the Material and Methods section.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Chen et al., highlight a technical confound in previous publications that claim attenuation of PTBP1 results in trans-differentiation of astrocytes into dopamine neurons. While they clearly observe that previous use of recombinant AAV vectors lead to EGFP expression in dopaminergic neurons despite using an astrocyte &quot;specific&quot; promoter, the authors cannot conclude from the presented experiments that attenuation of PTBP1 does not achieve trans-differentiation. This is because the use of AAV could render astrocytes unable to differentiate into dopaminergic neurons in response to successful downregulation of PTBP1. Adding other, AAV independent, means of achieving PTBP1 downregulation in astrocytes in vivo would strengthen this study.</p></disp-quote><p>We deeply appreciate Reviewer 3’s constructive suggestions. We injected antisense oligonucleotide (ASO) against mouse <italic>Ptbp1</italic> in the substantia nigra of lineage-tracing mice with or without 6-OHDA lesions for 2 months. While astroglial PTBP1 was efficiently repressed after ASO delivery for 2 months (Figure 4—figure supplement 1), no neurons, including DAn expressing astroglial tracing reporter, were detected, indicating that no neurons, including DAn, were converted from quiescent or reactive astrocytes after ASO-<italic>Ptbp1</italic> delivery (Figure 4B, D). Moreover, motor deficits in 6-OHDA lesion mice did not improve 2 months after ASO-<italic>Ptbp1</italic> delivery. These results have been added to the revised manuscript (Figure 4E).</p><p>References</p><p>Brulet R, Matsuda T, Zhang L, Miranda C, Giacca M, Kaspar BK, Nakashima K, Hsieh J (2017) NEUROD1 Instructs Neuronal Conversion in Non-Reactive Astrocytes. Stem cell reports 8:1506-1515.</p><p>Grande A, Sumiyoshi K, Lopez-Juarez A, Howard J, Sakthivel B, Aronow B, Campbell K, Nakafuku M (2013) Environmental impact on direct neuronal reprogramming in vivo in the adult brain. Nature communications 4:2373.</p><p>Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G (2014) in vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. Cell stem cell 14:188-202.</p><p>Mattugini N, Bocchi R, Scheuss V, Russo GL, Torper O, Lao CL, Gotz M (2019) Inducing Different Neuronal Subtypes from Astrocytes in the Injured Mouse Cerebral Cortex. Neuron 103:1086-1095 e1085.</p><p>Qian H, Kang X, Hu J, Zhang D, Liang Z, Meng F, Zhang X, Xue Y, Maimon R, Dowdy SF, Devaraj NK, Zhou Z, Mobley WC, Cleveland DW, Fu XD (2020) Reversing a model of Parkinson's disease with in situ converted nigral neurons. Nature 582:550-556.</p><p>Wan J, Zhao XF, Vojtek A, Goldman D (2014) Retinal injury, growth factors, and cytokines converge on β-catenin and pStat3 signaling to stimulate retina regeneration. Cell Rep 9:285-297.</p><p>Wang LL, Serrano C, Zhong X, Ma S, Zou Y, Zhang CL (2021) Revisiting astrocyte to neuron conversion with lineage tracing in vivo. Cell.</p><p>Zhou H et al. (2020) Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice. Cell 181:590-603.e516.</p></body></sub-article></article>